LONZA

Lonza is buying five production sites in the US, along with about 1,100 employees, from Merck KGaA for a low- to mid‑three‑digit million Swiss franc sum. The transaction is expected to close in mid‑2027; the acquired operations are projected to contribute roughly CHF 250 million in revenue in 2028. The takeover strengthens Lonza’s capacity in ADCs, bioconjugates, viral vectors and lipid nanoparticles and enables broader support from clinical development through commercial production; margins will initially be below the group average but are planned to reach group levels by the mid‑2030s. Payment will be made entirely in cash using available funds and credit lines, with the BBB+ credit rating to be maintained. » More on deraktionaer.de

Lonza is expanding commercial-scale production of bioconjugates in Visp and now plans three multi-product plants; commercial production is to begin in 2028. Existing facilities will be converted to 500-liter single-use technology by 2027 to speed product integration and serve customer programs more flexibly. The move responds to rising demand for antibody–drug conjugates (ADCs) and other bioconjugates. Lonza shares traded about 1.4% higher at CHF 638.80 at one point. » More on finanzen.net

Numerous corporate results and events are scheduled for 14 October: Lonza will report Q3 revenue, ASML and several US banks including Blackrock, Bank of America, Morgan Stanley and State Street will publish Q3 figures. There are also pre-close calls from Airbus and Schaeffler, plus other company and investor appointments. On the economic front, China's trade balance, US consumer prices and the Fed's Beige Book will be released; additionally, the Bundestag plans a government statement by Chancellor Friedrich Merz. » More on finanzen.net

Lonza and US company Asimov agree a strategic collaboration to advance production of lentiviral vectors for in‑vivo applications. Asimov contributes cell line technologies; Lonza provides process development, upscaling, analytics and GMP manufacturing. The aim is to develop stable production systems and to optimize genetic sequences and processes up to clinical and commercial production. Lonza shares rose briefly in SIX trading. » More on finanzen.net

Lonza is developing an aseptic spray drying process at its Bend (USA) site to enable high‑concentration formulations of biologics such as monoclonal antibodies, antibody‑drug conjugates (ADCs) and peptides. Initial tests showed various antibodies and ADCs can be reliably spray dried, with the aim of creating new solutions for high‑dose subcutaneous applications. The process is intended to improve stability and reduce viscosity but still faces technical hurdles such as protein stability, sterile processing, formulation optimization and scaling to industrial production. The Lonza share was at times 0.64% lower at 571.53 francs. » More on finanzen.net